Constarium
← Search

Omics · study · 2026

A novel nanobody-based TCR-like CAR-T therapy targeting PRAME for the treatment of acute myeloid leukemia

Listed in NCBI GEO

Chimeric antigen receptor (CAR) T-cell immunotherapy in acute myeloid leukemia (AML) remains challenging, primarily due to the lack of specific cell surface antigens that are highly expressed on leukemic blasts but largely absent on hematopoietic stem/progenitor cells and healthy tissues.

Description

TCR-like CAR-T therapy targeting intracellular antigens provides a novel strategy for the treatment of AML. In this study, we aimed to develop nanobodies targeting the intracellular antigen PRAME and to establish a novel nanobody-based TCR-like CAR-T cell therapy directed against the peptide-MHC complex PRAME425-433/HLA-A2.

Links

Topics

From keywords
Life Sciences
Provenance · 1 source records, 7 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE32043811 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title